Compare TVTX & MC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TVTX | MC |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.9B |
| IPO Year | 2013 | 2014 |
| Metric | TVTX | MC |
|---|---|---|
| Price | $56.17 | $68.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $40.62 | ★ $72.88 |
| AVG Volume (30 Days) | ★ 1.8M | 891.6K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.88% |
| EPS Growth | ★ 92.89 | N/A |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | N/A |
| Revenue This Year | $44.76 | $18.28 |
| Revenue Next Year | $35.51 | $17.22 |
| P/E Ratio | ★ N/A | $89.39 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.03 | $51.06 |
| 52 Week High | $60.10 | $78.22 |
| Indicator | TVTX | MC |
|---|---|---|
| Relative Strength Index (RSI) | 55.14 | 53.13 |
| Support Level | $54.87 | $68.19 |
| Resistance Level | $59.89 | $72.13 |
| Average True Range (ATR) | 2.37 | 2.55 |
| MACD | -0.66 | 0.16 |
| Stochastic Oscillator | 46.64 | 57.50 |
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.